Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200481 | 1.00 | TSHR (0.53) | TSHRTHRBCA2TRPA1HSD17B10 | |
| SCHEMBL199323 | 1.00 | TSHR (0.53) | TSHRTHRBCA2TRPA1HSD17B10 | |
| SCHEMBL200459 | 1.00 | TSHR (0.53) | TSHRTHRBCA2TRPA1HSD17B10 | |
| SCHEMBL12749540 | 1.00 | TSHR (0.53) | TSHRTHRBCA2TRPA1HSD17B10 | |
| SCHEMBL200935 | 1.00 | — | — | |
| SCHEMBL22214867 | 1.00 | TSHR (0.53) | TSHRTHRBCA2TRPA1HSD17B10 | |
| SCHEMBL387242 | 1.00 | TSHR (0.53) | TSHRTHRBCA2TRPA1HSD17B10 | |
| SCHEMBL198940 | 1.00 | TSHR (0.53) | TSHRTHRBCA2TRPA1HSD17B10 | |
| SCHEMBL198830 | 1.00 | TSHR (0.53) | TSHRTHRBCA2TRPA1HSD17B10 | |
| SCHEMBL200493 | 1.00 | TSHR (0.53) | TSHRTHRBCA2TRPA1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
| US-20230338411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| CN-110462502-B | Method for manufacturing liquid crystal element | JSR株式会社 | 2022-05-17 | — | — | CN | disclosed |
| CN-111718728-A | Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal element | JSR株式会社 | 2020-09-29 | — | — | CN | disclosed |
| EP-3331895-B1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF USEFUL AS ANTIVIRAL AGENTS | CHIMERIX INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20170037399-A1 | CHIRAL DESIGN | WAVE LIFE SCIENCES LTD. (SG) | 2017-02-09 | — | — | US | disclosed |
| US-20150211006-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2015-07-30 | — | — | US | disclosed |
| US-8481736-B2 | Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof | BASF SE (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8088922-B2 | Dibenzorylenetetracarboximides as infrared absorbers | BASF AKTIENGESELLSCHAFT (DE) | 2012-01-03 | — | — | US | disclosed |
| WO-2007138051-A1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | BASF SE (DE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007116001-A2 | LIQUID CRYSTALLINE RYLENE TETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF | BASF SE (DE) | 2007-10-18 | — | — | WO | disclosed |
| EP-1843407-A1 | Liquid crystalline rylenetetracarboxylic acid derivatives and their use | BASF AKTIENGESELLSCHAFT (DE) | 2007-10-10 | — | — | EP | disclosed |
| EP-0691327-B1 | AMINE DERIVATIVE AND DERMATOLOGIC PREPARATION CONTAINING THE SAME | KAO CORP (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5723497-A | AMINE ALCOHOL DERIVATIVES FOR WRINKLE RESISTNCE | KAO CORPORATION (JP) | 1998-03-03 | — | — | US | disclosed |
| EP-0691327-A1 | AMINE DERIVATIVE AND DERMATOLOGIC PREPARATION CONTAINING THE SAME | Kao Corporation (JP) | 1996-01-10 | — | — | EP | disclosed |
| EP-0064441-B1 | BIOCIDAL COMPOSITION BASED ON SULFONIUM SALTS AND ORGANO TIN COMPOUNDS | SOCIETE NATIONALE ELF AQUITAINE (FR) | 1984-09-26 | — | — | EP | disclosed |
| US-4166038-A | OIL RECOVERY | MOBIL OIL CORPORATION (US) | 1979-08-28 | — | — | US | disclosed |
| US-4060495-A | GERMICIDAL DETERGENT | LEVER BROTHERS COMPANY (US) | 1977-11-29 | — | — | US | disclosed |
| US-4034046-A | GERMICIDES | LEVER BROTHERS COMPANY (US) | 1977-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | TSHR 2262/4885THRB 2609/4885CA2 1829/4885 |
| US-20150211006-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | TSHR 3259/4885THRB 2995/4885CA2 904/4885 |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, NPC1L1, NPC1 | TSHR 3323/4885THRB 4690/4885CA2 4324/4885 |
| US-20230338411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | TSHR 2262/4885THRB 2609/4885CA2 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.